Scottish company Lamellar Biomedical raises £3.3 million from Institutional investors
Released: Tuesday 8th January 2013
Edinburgh, 7 January 2013: Lamellar Biomedical is pleased to announce that it has raised £3.3
million in equity financing from existing and new shareholders including Barwell, Scottish Enterprise
and TRI Cap angel investors. Funds managed by Invesco Perpetual form the core of the new
shareholding.
The proceeds of the offering will be used to further develop the Company’s lead product, LMS-611.
The company has been advised by a Notified Body that LMS-611 will be regulated as a class 2b
medical device for the treatment of dry eye disease (DED) and Radiotherapy Induced Xerostomia
(RIX), commonly known as dry mouth. Lamellar Biomedical has been successful in forging strong
links with the Scottish clinical community and is pleased to be working with the Vision Sciences Unit
at Glasgow Caledonian University and the Beatson West of Scotland Cancer Centre respectively in
these development programs.
Additionally Lamellar Biomedical is progressing with a clinical program to investigate the role of
LMS-611 as a medicinal product in cystic fibrosis. This program is being led by the West of Scotland
Cystic Fibrosis unit led by Dr Steve Bicknell and Dr Gordon MacGregor.
On the research front Lamellar has been successful in applying for three PhD studentships which will
be held at the Roslin Institute and the Universities of Glasgow and Strathclyde.
Following the completion of the financing Dr Duncan Moore has been elected as Chairman of the
Company. Duncan Moore is a Partner at East West Capital Partners and was previously Global Head
of healthcare equity research at Morgan Stanley.
About Lamellar
Lamellar Biomedical Ltd was established in June 2007 when the founding Directors of the Company,
recognising the considerable therapeutic potential of Lamellasomes™, acquired the intellectual
property rights to the technology.
The Company benefits from an entrepreneurial Board of Directors and Management Team, a Scientific
Advisory Board of eminent scientists and a Research Team with intimate knowledge of lamellar body
physiology and pathology.
Contacts:
Dr Alec McLean
CEO
Tel: +441698748832
Dr Duncan Moore
Chairman
Tel; +447785971715
